https://www.selleckchem.com/pr....oducts/ferrostatin-1
The frequency of cTfh within CD4 T cells was more closely associated with disease severity than the serum anti-AchR antibody titer and frequency of plasmablasts within B cells. Abnormalities of cTfh were improved after immunotherapy in parallel with clinical improvement. Alternation of cTfh is a key feature in the development of MG and may become a biomarker for disease severity and therapeutic efficacy. This study provides Class II evidence that the level of cTfh is associated with disease severity in patients with MG. This study
Like
Comment
Share
